MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
PR Newswire

Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study

- Growing body of evidence shows matrix of polyphenols, as provided in Longevinex(R), exert greater benefit than resveratrol alone. 150-year lifespan not far off?

— SAN DIMAS, California, March 31

SAN DIMAS, California, March 31 /PRNewswire/ -- While molecular biologists and news reporters present jaw-dropping evidence that a red wine molecule called resveratrol may usher in the advent of anti-aging pills, other researchers report that a matrix of small natural molecules, such as those in Longevinex(R), exert far greater effects than resveratrol alone. For example, a recently reported human study found the Longevinex(R) dietary supplement is superior to green tea.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080331/CLM261 )

And while Barbara Walters (ABC News) interviews senior Americans who are living vibrantly active lives beyond the age of 100, she also interviews experts who now say small molecules that can influence the genetic machinery within living cells, concentrated in pill form, may make it possible for Americans to live 150 healthy years on a regular basis.

An optimal matrix for nutraceuticals would provide molecules found in grapes, sesame seeds, onions and apple peels which appear to work additively and synergistically, even exerting a greater effect upon the human genome than plain resveratrol.

While many of the beneficial effects of these natural molecules appear to be dose dependent, requiring doses that exceed those found in foods, there may be diminishing returns when supra-high doses of these molecules are employed.

For example, one study shows that extreme doses resveratrol may impair the uptake of folic acid (vitamin B9) by intestinal cells. Folic acid is an essential nutrient required for repair of DNA gene strands and is utilized by the body to limit the amount of an undesirable blood protein called homocysteine.

Optimal health benefits appear to be achieved when consuming an array of polyphenolic molecules in the range of (100-200 milligrams), as provided in 2-3 glasses of aged red wine, or in well-designed nutraceuticals like Longevinex(R), which contain no alcohol. Supra-high dose resveratrol pills (500 mg or more) have recently been introduced, which may be counterproductive. For example, Achilles heel tendonitis is now widely reported when using supra-high dose resveratrol pills.

Late in 2007 Steven R McAnulty, Ph.D., Associate Professor in the Health, Leisure, and Exercise Science department at Appalachian State University, in the first successful human study of a resveratrol supplement, reported that Longevinex(R), but not the primary active molecule (catechin) in green tea, significantly reduces markers of oxidation and inflammation among endurance athletes at modest doses. The results of that study were eventually reported at the Annual Meeting of the American College of Sports Medicine, Southeast Chapter in February, 2008.

For more information about Longevinex, please visit: www.longevinex.com or call +1-866-405-4000.

Web site: http://www.longevinex.com

Related news

Clients in focus...

Get the Flash Player to see this rotator.

Partnering discussion free of charge
BioTrinity
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us